

DIMICCO DANIEL R
 Form 4
 July 01, 2011

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 DIMICCO DANIEL R

(Last) (First) (Middle)
 526 S. CHURCH STREET
 (Street)
 CHARLOTTE, NC 28202
 (City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 Duke Energy CORP [DUK]

3. Date of Earliest Transaction
 (Month/Day/Year)
 06/30/2011

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)		
				(A) or (D)	Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Underlying Securities (Instr. 3 and 4)
--	------------------------------------	--------------------------------------	--	--------------------------------	---	--	---	--

Edgar Filing: DIMICCO DANIEL R - Form 4

Derivative Security	(A) or Disposed of (D) (Instr. 3, 4, and 5)	Code	V	(A)	(D)	Date	Expiration	Title	Amount or Number of Shares	
						Exercisable	Date			
Phantom Stock										
Director Savings Plan		A		1,089		(2)	(3)	Common Stock	1,089	\$ 18

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
DIMICCO DANIEL R 526 S. CHURCH STREET CHARLOTTE, NC 28202			X	

Signatures

/s/ David S. Maltz, attorney-in-fact for Daniel R.
DiMicco

07/01/2011

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Converts to Common Stock on a 1-for-1 basis.
- (2) Generally payable upon reporting person's termination of service.
- (3) Expiration date not applicable.
- (4) Includes additional securities acquired pursuant to regular dividend reinvestments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. New Roman" style="font-size:10.0pt;">848,721

\$

1,068,034

TOTAL CONVERTIBLE SECURITIES AND WARRANTS

(Cost \$51,767,368)

\$

37,942,172

SHARES

COMMON STOCKS AND WARRANTS 82.6%

Biotechnologies/Biopharmaceuticals 24.3%

	241,651
Acorda Therapeutics Inc. (b)	
	6,094,438
	11,800
Alexion Pharmaceuticals, Inc. (b)	
	576,076
	252,444
Amgen Inc. (b)	
	14,280,757
	145,500
Amylin Pharmaceuticals, Inc. (b)	

Edgar Filing: DIMICCO DANIEL R - Form 4

	2,064,645
	5,894,849
Antisoma plc (b) (e)	
	3,141,365
	118,000
Athersys, Inc. warrants (Restricted, expiration 6/08/12) (a) (b)	
	24,780
	296,744
Celgene Corporation (b)	
	16,522,705
	121,750
Cephalon, Inc. (b) (i)	
	7,598,418
	211,280

Edgar Filing: DIMICCO DANIEL R - Form 4

Cubist Pharmaceuticals, Inc. (b)

4,007,982

165,619

Genzyme Corporation (b)

8,116,987

286,884

Gilead Sciences, Inc. (b)

12,416,340

76,175

Martek Biosciences Corporation (b)

1,442,755

69,610

OSI Pharmaceuticals, Inc. (b)

2,159,998

Explanation of Responses:

138,720

United Therapeutics Corporation (b)

7,303,608

188,708

XenoPort, Inc. (b)

3,502,420

89,253,274

Drug Delivery 0.5%

568,311

Penwest Pharmaceuticals Co. (b)

Explanation of Responses:

Edgar Filing: DIMICCO DANIEL R - Form 4

SHARES		VALUE
Drug Delivery continued		
287,106	Penwest Pharmaceuticals Co. warrants (Restricted, expiration 3/11/13) (a) (b)	\$ 292,848
		1,764,774
Drug Discovery Technologies 0.1%		
11,441	Clinical Data, Inc. (b)	208,913
243,433	Clinical Data, Inc. CVR (Restricted) (a) (b) (f)	41,784
70	Zyomyx, Inc. (Restricted) (a) (b)	18
		250,715
Generic Pharmaceuticals 10.1%		
1,321,151	Akorn, Inc. (b)	2,364,860
202,223	Akorn, Inc. warrants (Restricted, expiration 3/08/11) (a) (b)	48,533
273,934	Impax Laboratories, Inc. (b)	3,725,502
169,148	Mylan Inc. (b)	3,117,398
178,300	Perrigo Company	7,103,472
369,487	Teva Pharmaceutical Industries, Ltd. (g)	20,757,780
		37,117,545
Healthcare Services 15.3%		
286,221	Aetna Inc.	9,073,205
222,222	Aveta, Inc. (Restricted) (a) (b) (h)	2,222,220
116,446	Charles River Laboratories International, Inc. (b)	3,923,066
335,200	CVS Caremark Corporation	10,796,792
131,476	Laboratory Corporation of America Holdings (b)	9,839,664
70,514	Medco Health Solutions, Inc. (b) (i)	4,506,550
256,320	Pharmaceutical Product Development, Inc.	6,008,141
169,359	WellPoint, Inc. (b)	9,871,936
		56,241,574
Medical Devices and Diagnostics 23.7%		
528,630	Align Technology, Inc. (b)	9,420,187
71,016	Becton, Dickinson and Company	5,600,322
509,696	Hologic, Inc. (b)	7,390,592
179,487	IDEXX Laboratories, Inc. (b)	9,591,786
173,229	Illumina, Inc. (b)	5,309,468
18,045	Intuitive Surgical, Inc. (b)	5,473,409
217,414	Inverness Medical Innovations, Inc. (b)	9,024,855
44,155	Johnson & Johnson	2,844,024
130,780	Life Technologies Corporation (b)	6,830,639
109,720	Masimo Corporation (b)	3,337,682
160,000	Masimo Laboratories, Inc. (Restricted) (a) (b)	102,211
830,292	Medwave, Inc. (b) (c)	6,642
207,573	Medwave, Inc. warrants (Restricted, expiration 8/21/11) (a) (b) (c)	0
96,232	Myriad Genetics, Inc. (b)	2,511,655
93,008	OmniSonic Medical Technologies, Inc. (Restricted) (a) (b)	93
474,391	PerkinElmer, Inc.	9,767,711

SHARES		VALUE
Medical Devices and Diagnostics continued		
208	Songbird Hearing, Inc. (Restricted) (a) (b)	\$ 139
197,877	Stryker Corporation	9,967,065
		87,178,480
Pharmaceuticals 8.6%		
91,945	Abbott Laboratories	4,964,111
359,001	Forest Laboratories, Inc. (b)	11,527,522
363,063	Pfizer Inc.	6,604,116
25,852	Shire plc (g)	1,517,512
241,885	Warner Chilcott plc (b) (i)	6,886,466
		31,499,727
TOTAL COMMON STOCKS AND WARRANTS		
(Cost \$288,138,567)		\$ 303,306,089
PRINCIPAL AMOUNT		
SHORT-TERM INVESTMENTS 6.9%		
\$ 10,000,000	General Electric Capital Co., 0.12% due 01/04/10	9,999,900
13,600,000	General Electric Capital Co., 0.01% due 01/08/10	13,599,974
1,785,000	General Electric Capital Co., 0.02% due 01/15/10	1,784,986
TOTAL SHORT-TERM INVESTMENTS		
(Cost \$25,384,860)		\$ 25,384,860
TOTAL INVESTMENTS - 99.9%		
(Cost \$365,290,795)		\$ 366,633,121
OTHER ASSETS IN EXCESS OF LIABILITIES - 0.1%		\$ 393,727
NET ASSETS - 100%		\$ 367,026,848

-
- (a) Security fair valued.
- (b) Non-income producing security.
- (c) Affiliated issuers in which the Fund holds 5% or more of the voting securities (total market value of \$18,090,389).
- (d) Number of warrants to be determined at a future date.
- (e) Foreign security.
- (f) Contingent Value Rights
- (g) American Depositary Receipt
- (h) Security exempt from registration under Rule 144A of the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers.
- (i) A portion of security is pledged as collateral for call options written.

H&O HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

DECEMBER 31, 2009

(Unaudited)

(Continued)

SCHEDULE OF WRITTEN OPTIONS

NUMBER OF CONTRACTS (100 SHARES EACH)		EXPIRATION DATE	CURRENT VALUE
CALL OPTIONS WRITTEN			
159	Cephalon, Inc., strike @ 60	Jan - 2010	\$ (54,060)
140	Medco Health Solutions, Inc., strike @ 65	Jan - 2010	(10,500)
40	Warner Chilcott plc, strike @ 30	Jan - 2010	(800)
TOTAL CALL OPTIONS WRITTEN			
	(Premiums received \$54,680)		\$ (65,360)

Other Information Financial Accounting Standards Board Accounting Standards Codification No. 820, Fair Value Measurements and Disclosures, establishes a three-tier hierarchy to prioritize the assumptions, referred to as inputs, used in valuation techniques to measure fair value. The three-tier hierarchy of inputs is summarized in the three broad levels listed below:

- Level 1 quoted prices in active markets for identical investments
- Level 2 prices determined using other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)
- Level 3 prices determined using significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments)

These inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used as of December 31, 2009 to value the Fund's net assets:

Edgar Filing: DIMICCO DANIEL R - Form 4

	Level 1	Level 2	Level 3	Total
Assets at Value				
Convertible Securities and Warrants				
Biotechnologies/Biopharmaceuticals			\$ 3,942,057	\$ 3,942,057
Drug Discovery Technologies			4,874,746	4,874,746
Healthcare Services			5,255,869	5,255,869
Medical Devices and Diagnostics			23,869,500	23,869,500
Total Convertible Securities and Warrants			37,942,172	37,942,172
Common Stocks and Warrants				
Biotechnologies/Biopharmaceuticals	\$ 89,228,494		24,780	89,253,274
Drug Delivery	1,471,926		292,848	1,764,774
Drug Discovery Technologies	208,913		41,802	250,715
Generic Pharmaceuticals	37,069,012		48,533	37,117,545
Healthcare Services	54,019,354		2,222,220	56,241,574
Medical Devices and Diagnostics	87,076,037		102,443	87,178,480
Pharmaceuticals	31,499,727			31,499,727
Total Common Stocks and Warrants	300,573,463		2,732,626	303,306,089
Short-Term Investments		\$ 25,384,860		25,384,860
Other Assets			534,997	534,997
Total Assets at Value	\$ 300,573,463	\$ 25,384,860	\$ 41,209,795	\$ 367,168,118
Liabilities at Value				
Options Contracts Written	\$ 65,900	\$	\$	\$ 65,900

The following is a reconciliation of Level 3 assets for which significant unobservable inputs were used to determine fair value:

Level 3 Assets	Balance as of September 30, 2009	Accrued discounts/ premiums	Realized gain (loss) and change in unrealized appreciation (depreciation)	Net purchases/ sales	Net transfers in (out of) Level 3	Balance as of December 31, 2009
Convertible Securities and Warrants						
Biotechnologies/Biopharmaceuticals	\$ 2,690,796		\$ 1,134,542	\$ 116,719		\$ 3,942,057
Drug Discovery Technologies	4,874,746					4,874,746
Healthcare Services	5,255,869					5,255,869
Medical Devices and Diagnostics	27,394,646		(3,792,070)	266,924		23,869,500
Common Stocks and Warrants						
Biotechnologies/Biopharmaceuticals	277,541		32,817		\$ (285,578)	24,780
Drug Delivery	267,009		25,839			292,848
Drug Discovery Technologies	38,163		3,639			41,802
Generic Pharmaceuticals	30,333		18,200			48,533
Healthcare Services	2,222,220					2,222,220
Medical Devices and Diagnostics	69,480		32,963			102,443
Other Assets	922,146		293,018	(680,167)		534,997
Total	\$ 44,042,949		\$ (2,251,052)	\$ (296,524)	\$ (285,578)	\$ 41,209,795
Net change in unrealized appreciation (depreciation) from investments still held as of December 31, 2009						\$ (2,557,129)

Investment Valuation Investments traded on national securities exchanges or in the over-the-counter market that are National Market System securities are valued at the last sale price or, lacking any sales, at the mean between the last bid and asked prices. Other over-the-counter securities are valued at the most recent bid prices as obtained from one or more dealers that make markets in the securities. Publicly traded investments for which market quotations are not readily available or whose quoted price may otherwise not reflect fair value and the fair value of venture capital and other restricted securities are valued in good faith by the Adviser pursuant to valuation policies and procedures approved by the Trustees. Such values are subject to regular oversight and ratification by the Trustees. Because of the uncertainty of fair valuations, these estimated values may differ significantly from the values that would have been used had a ready market for these securities existed, and the differences could be material. Each such fair value determination is based on a consideration of relevant factors. Factors the Adviser considers may include (i) the existence of any contractual restrictions on the disposition of securities; (ii) information obtained from the issuer, which may include an analysis of the company's financial statements, the company's products or intended markets or the company's technologies; (iii) the price of a security negotiated at arm's length in an issuer's completed subsequent round of financing; and (iv) the price and extent of public trading in similar securities of the issuer or of comparable companies. Short-term investments with maturity of 60 days or less are valued at amortized cost, which approximates fair value.

Venture Capital and Other Restricted Securities The Fund may invest in venture capital and other restricted securities if these securities would currently comprise 40% or less of net assets. The value of these securities represents 11% of the Fund's net assets at December 31, 2009. The following table details the acquisition date, cost, carrying value per unit, and value of the Fund's venture capital and other restricted securities at December 31, 2009. The Fund on its own does not have the right to demand that such securities be registered.

Edgar Filing: DIMICCO DANIEL R - Form 4

Security (j)	Acquisition Date	Cost	Carrying Value per Unit	Value
Agilix Corporation				
Series B Cvt. Pfd.	11/08/01	\$ 2,495,500	\$ 0.06	\$ 141,809
Akorn, Inc.				
Warrants (expiration 3/08/11)	3/07/06	0.00	0.24	48,533
Athersys, Inc.				
Warrants (expiration 6/08/12)	6/07/07	0.00	0.21	24,780
Aveta, Inc.				
Common	12/21/05	3,004,731	10.00	2,222,220
CardioKinetix, Inc.				
Series C Cvt. Pfd.	5/22/08	2,367,320	0.69	2,359,999
Cvt. Promissory Note	12/10/09	188,863	1.00	188,863
Warrants (expiration 12/11/19)	12/10/09	94	0.00	0
Ceres, Inc.				
Series C Cvt. Pfd.	12/23/98	1,502,732	6.50	2,437,500
Series C-1 Cvt. Pfd.	3/31/01	111,508	6.50	209,255
Series D Cvt. Pfd.	3/14/01	1,668,294	6.50	1,820,683
Series F Cvt. Pfd.	9/05/07	268,136	6.50	265,499
Warrants (expiration 9/05/15)	9/05/07	0.00	0.00	0
Clinical Data, Inc.				
Contingent Value Rights	5/28/09	0.00	0.17	41,784
Concentric Medical, Inc.				
Series B Cvt. Pfd.	5/07/02, 1/24/03	3,330,988	0.52	2,523,529
Series C Cvt. Pfd.	12/19/03	1,500,818	0.52	906,977
Series D Cvt. Pfd.	9/30/05	958,007	0.52	355,160
Series E Cvt. Pfd.	12/18/08	655,011	0.52	339,047
Elemé Medical, Inc.				
Series C Cvt. Pfd.	7/15/08	3,253,120	0.54	927,636
Subordinated Cvt. Promissory Note	12/18/09	71,201	1.00	69,858
FlowCardia, Inc.				
Series C Cvt. Pfd.	8/29/07	2,475,591	1.07	2,458,333
Interlace Medical, Inc.				
Series C Cvt. Pfd.	6/10/09	2,072,857	1.10	2,065,000
Labcyte Inc.				
Series C Cvt. Pfd.	7/18/05	1,924,893	0.52	1,920,000
MacroGenics, Inc.				
Series D Cvt. Pfd.	9/04/08	1,002,546	0.65	199,812
Series D Cvt. Pfd. 18 Month Lock-up	9/04/08	315,748	0.00	0
Magellan Biosciences, Inc.				
	11/28/06,			
Series A Cvt. Pfd.	11/04/09	3,117,537	1.00	3,109,861
Warrants (expiration 4/01/19)	4/03/09	0.00	0.00	0
Warrants (expiration 5/06/19)	5/12/09	0.00	0.00	0
Masimo Laboratories, Inc.				
Common	3/31/98	0.00	0.64	102,211
Medwave, Inc.				
Warrants (expiration 8/21/11)	8/21/06	0.00	0.00	0
OmniSonic Medical Technologies, Inc.				
Series A-1 Cvt. Pfd.	10/01/03	1,801,555	0.001	1,548
Series B-1 Cvt. Pfd.	6/04/07, 11/15/07	961,365	0.001	1,263
Common	5/24/01, 7/02/07	2,409,096	0.001	93
Palyon Medical Corporation				
Series A Cvt. Pfd.	4/28/09	2,967,403	0.21	2,950,000
Penwest Pharmaceuticals Co.				
Warrants (expiration 3/11/13)	3/11/08	0.00	1.02	292,848
PHT Corporation				
Series D Cvt. Pfd.	7/23/01	4,205,754	0.78	4,200,000

Edgar Filing: DIMICCO DANIEL R - Form 4

Series E Cvt. Pfd.	9/12/03 - 10/14/04	941,669	0.78	939,506
Series F Cvt. Pfd.	7/21/08	122,580	0.78	116,363
Songbird Hearing, Inc.				
Common	12/14/00	3,004,861	0.67	139
TargeGen, Inc.				
Series C Cvt. Pfd.	8/30/05	2,763,495	1.30	2,760,000
Series D Cvt. Pfd.	5/08/07	764,407	1.30	762,932
Cvt. Promissory Note	9/08/09, 10/09/09	226,375	1.00	219,313
TherOx, Inc.				
Series H Cvt. Pfd.	9/11/00	3,002,748	1.66	108,181
Series I Cvt. Pfd.	7/08/05	579,958	1.66	247,939
Warrants (expiration 1/26/11)	1/26/05	0.00	0.00	0
Warrants (expiration 6/09/10)	6/09/04	0.00	0.00	0
Xoft, Inc.				
Series D Cvt. Pfd.	3/23/07	2,958,518	2.50	2,304,688
Series E Cvt. Pfd.	6/20/08	592,532	2.50	441,618
Cvt. Promissory Note	6/12/09	598,183	1.00	590,000
Warrants (expiration 6/12/14)	6/12/09	59	0.00	0
Zyomyx, Inc.				
Common	2/19/99 - 7/22/04	3,902,233	0.25	18
		\$ 64,088,286		\$ 40,674,798

(j) See Schedule of Investments and corresponding footnotes for more information on each issuer.

Edgar Filing: DIMICCO DANIEL R - Form 4

Federal Income Tax Cost - At December 31, 2009, the total cost of securities for Federal income tax purposes was \$365,290,795. The net unrealized gain on securities held by the Fund was \$1,342,326, including gross unrealized gain of \$45,358,715 and gross unrealized loss of \$44,016,389.

Affiliate Transactions - An affiliate issuer is a company in which the Fund holds 5% or more of the voting securities. Transactions with such companies during the period ended December 31, 2009 were as follows:

Issuer	Value on October 1, 2009	Purchases	Sales	Income	Value on December 31, 2009
Agilix Corporation	\$ 141,809		\$		\$ 141,809
CardioKinetix, Inc.	2,359,999	\$ 188,957		\$ 468	2,548,862
Concentric Medical, Inc.	7,932,139				4,124,713
Elemé Medical, Inc.	910,393	69,858		265	997,494
Interlace Medical, Inc.	2,065,000				2,065,000
Medwave, Inc.	16,606				6,642
Palyon Medical Corporation	2,950,000				2,950,000
PHT Corporation	5,255,869				5,255,869
	\$ 21,631,815	\$ 258,815	\$	\$ 733	\$ 18,090,389

Item 2. Controls and Procedures.

(a) The registrant's principal executive officer and principal financial officer have concluded, based on their evaluation of the registrant's disclosure controls and procedures as conducted within 90 days of the filing date of this report, that these disclosure controls and procedures are adequately designed and are operating effectively to ensure that information required to be disclosed by the registrant on Form N-Q is (i) accumulated and communicated to the investment company's management, including its certifying officers, to allow timely decisions regarding required disclosure; and (ii) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms.

(b.) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act that occurred during the registrant's last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

Item 3. Exhibits.

Separate certifications for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a) under the Act (17 CFR 270.30a-2(a)). Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant) H&Q Healthcare Investors

By (Signature and Title) /s/ Daniel Omstead
Daniel Omstead, President

Date 3/1/2010

Pursuant to the requirements of the Securities and Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By (Signature and Title) /s/ Laura Woodward
Laura Woodward, Treasurer

Date 3/1/2010
